Metformin and β‐cell function in insulin‐treated patients with type 2 diabetes: A randomized placebo‐controlled 4.3‐year trial

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 20, Iss. 3, 2018-03 ,pp. : 730-733

John Wiley & Sons Inc

Access to resources Recommend Favorite

Peri‐operative management of patients with type‐2 diabetes mellitus undergoing non‐cardiac surgery using liraglutide, glucose–insulin–potassium infusion or intravenous insulin bolus regimens: a randomised controlled trial

By  

ANAESTHESIA, Vol. 73, Iss. 3, 2018-03 ,pp. : 332-339

John Wiley & Sons Inc

Access to resources Recommend Favorite

A randomized, double‐blind, placebo‐controlled, phase II clinical trial to investigate the efficacy and safety of oral DA‐1229 in patients with type 2 diabetes mellitus who have inadequate glycaemic control with diet and exercise

By  

DIABETES/METABOLISM: RESEARCH AND REVIEWS (ELECT), Vol. 31, Iss. 3, 2015-03 ,pp. : 295-306

John Wiley & Sons Inc

Access to resources Recommend Favorite

Efficacy and safety of liraglutide versus placebo added to basal insulin analogues (with or without metformin) in patients with type 2 diabetes: a randomized, placebo‐controlled trial

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 17, Iss. 11, 2015-11 ,pp. : 1056-1064

John Wiley & Sons Inc

Access to resources Recommend Favorite

Improved glycaemic control with BIAsp 30 in insulin-naïve type 2 diabetes patients inadequately controlled on oral antidiabetics: subgroup analysis from the IMPROVE study

By Wenying Yang   Benroubi Marian   Borzi Vito   Gumprecht Janusz   Kawamori Ryuzo   Shaban Joseph   Shah Siddharth   Shestakova Marina   Ligthelm Robert   Valensi Paul  

Current Medical Research and Opinion, Vol. 25, Iss. 11, 2009-11 ,pp. : 2643-2654

Informa Healthcare

Access to resources Recommend Favorite